Indian AI Tool for Cancer Care Spotlighted at BRICS Health Summit
iOncology.ai, developed by AIIMS and C-DAC, gains attention for its potential to transform cancer care in emerging economies.
An innovative Indian artificial intelligence platform, iOncology.ai, developed to enhance cancer care, was highlighted at the recent BRICS Summit through a feature in the BRICS Health Journal. This platform, a collaboration between the All India Institute of Medical Sciences (AIIMS), New Delhi, and the Centre for Development of Advanced Computing (C-DAC), Pune, aims to revolutionize cancer treatment by integrating clinical data for early detection and treatment planning.
Focus on Early Detection and Treatment
iOncology.ai is designed to assist in early cancer detection, risk stratification, treatment planning, and patient data management. The platform is currently in its pilot phase, undergoing clinical validation to assess its efficacy in real-world settings. The developers, supported by the Ministry of Electronics and Information Technology, envision it as a tool to address disparities in cancer care, particularly in resource-limited settings.
Significance for Emerging Economies
The importance of this innovation is underscored by the fact that BRICS countries represent over 40% of the global population, with significant cancer incidence and mortality rates. The journal review, authored by Dr. Ashok Sharma and colleagues, emphasizes the potential of AI technologies like iOncology.ai to improve cancer screening and access to specialist care in these regions.
Dr. Sharma highlighted the opportunity for India to demonstrate how locally developed innovations can bridge cancer care gaps across the Global South. He stated, "Through BRICS collaboration, our focus should be on strengthening cancer prevention, early diagnosis, treatment, and therapy through evidence-based, interoperable solutions tailored to the needs of emerging economies."
Integration with National Health Initiatives
The platform aligns with India's broader cancer-control and digital-health efforts, including the Ayushman Bharat Digital Mission. It utilizes curated Indian datasets and plans to incorporate genetic data and electronic health records. However, the platform is still under research mode, with its diagnostic accuracy and clinical utility yet to be peer-reviewed.
Future steps for iOncology.ai involve prospective multicenter validation to confirm its effectiveness for broader clinical use. The developers aim to empower clinicians with tools that offer more equitable cancer care, especially in settings with limited resources.